Work

Abstract CT123: A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2)

Year: 2022

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2022-ct123

Authors: Ecaterina I. Dumbrava, Glenn J. Hanna, Gregory M. Cote, Thomas E. Stinchcombe, Melissa L. Johnson, Christopher T. Chen, Siddhartha H. Devarakonda, Naisargee Shah, Feng Xu, Robert C. Doebele, Mrinal M. Gounder

Institutions: The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, Massachusetts General Hospital, Duke University, Duke Medical Center, Duke Cancer Institute, Sarah Cannon, Stanford University, Washington University in St. Louis, Memorial Sloan Kettering Cancer Center, Cornell University

Language: English

Topic: Cancer-related Molecular Pathways

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4282914532

Cites:

Cited by:

Related to: 10